San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Reneo Pharmaceuticals is raising $94,769,998.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Gregory Flesher played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting. We are currently advancing a novel molecule into several diseases. Our experienced team of drug development experts, who have collaborated in many successful programs, are dedicated and passionate about finding effective therapies for these complex rare diseases.

To learn more about Reneo Pharmaceuticals, visit http://reneopharma.com/

Contact:
Gregory Flesher, President and Chief Executive Officer
858-283-0280
https://www.linkedin.com/in/gregory-j-flesher-962590/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved